GNUV205
/ GENUV
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 27, 2023
GNUV205, a bifunctional protein of engineered IL-2 fused with a novel anti-PD1 antibody, exhibits superior tumor suppressing efficacy in vivo
(SITC 2023)
- "Methods GNUV205 is an investigational immuno-cytokine molecule which comprises anti-PD-1 antibody (GNUV201) and engineered IL-2 (interleukin-2). We also confirmed GNUV205’s excellent tumor suppressing efficacy in other syngeneic tumor models such as B16F10 and Pan02. Conclusions In summary, these data strongly suggest that GNUV205 is a candidate-stage bifunctional immuno-cytokine for solid cancer therapy expected to overcome the limitations of current standard-of-care therapies, such as IL-2 or anti-PD-(L)1s."
Preclinical • Oncology • Solid Tumor • FCGR2A • FCGR2B • IL2 • IL2RG
October 13, 2022
Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Regresses Tumor Growth Without Toxicity
(Businesswire)
- "Genuv Inc...unveiled a new drug candidate, GNUV205, a fusion of engineered IL2 and anti-PD-1 antibody that advances immuno-oncology science. The drug candidate, for unspecified solid tumors, shows powerful anti-tumor activity without the toxicity typically associated with current IL-2 treatments....'Treatments targeting IL-2 are uniquely powerful, but have typically been plagued by systemic toxicity issues. Our strategy using a ‘no-alpha but attenuated beta gamma’ IL-2 variant fused with a unique anti-PD-1 via Genuv’s proprietary hetero Fc technology shows stronger binding affinity in the tumor microenvironment compared to marketed treatments Proleukine
®
, Keytruda
®
and Opdivo
®
without Treg cell expansion'."
Pipeline update • Preclinical • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1